5 Lung Cancer Clinical Trials in Cerritos, CA (2026)

Q: How do I join a clinical trial in Cerritos?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Cerritos research site will contact you.

Recruiting Lung Cancer Studies in Cerritos

NCT05899608Recruiting

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non...

Cerritos, CAPHASE31,600 participantsSummit Therapeutics

View Study Details

NCT06767514Recruiting

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival....

Cerritos, CAPHASE3780 participantsSummit Therapeutics

View Study Details

NCT05671510Recruiting

ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

The goal of this Phase 3 clinical trial is study the safety and efficacy of the nextgen anti-CTLA-4 antibody, gotistobart (ONC-392/BNT316), in patients with metastatic non-small cell lung cancer who h...

Cerritos, CAPHASE3630 participantsOncoC4, Inc.

View Study Details

NCT04613596Recruiting

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and ...

Cerritos, CAPHASE2626 participantsMirati Therapeutics Inc.

View Study Details

NCT06667076Recruiting

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth f...

Cerritos, CAPHASE2480 participantsJanssen Research & Development, LLC

View Study Details

About Lung Cancer Clinical Trials in Cerritos

Lung cancer is the leading cause of cancer death worldwide, starting in the cells of the lungs. The two main types are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Treatments include surgery, chemotherapy, radiation, immunotherapy, and targeted drugs.

There are currently 5 lung cancer clinical trials recruiting participants in Cerritos, CA. These studies are seeking a combined 4,116 participants. Research is being sponsored by Summit Therapeutics, OncoC4, Inc., Mirati Therapeutics Inc. and 1 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Lung Cancer Clinical Trials in Cerritos — FAQ

Are there lung cancer clinical trials in Cerritos?

Yes, there are 5 lung cancer clinical trials currently recruiting in Cerritos, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Cerritos?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Cerritos research site will contact you about next steps.

Are clinical trials in Cerritos free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Cerritos studies also compensate for your time and travel.

What lung cancer treatments are being tested?

The 5 active trials in Cerritos are testing new therapies including novel drugs, biologics, and treatment approaches for lung cancer.

Data updated July 22, 2026 from ClinicalTrials.gov